Baseline demographic and patient characteristics
| Characteristic | All patients (N=36) |
| Age—year | |
| Median (range) | 65.5 (43–76) |
| Sex—no. (%) | |
| Male | 24 (66.7) |
| Female | 12 (33.3) |
| ECOG performance status—no. (%) | |
| 0 | 36 (100) |
| Primary tumor location—no. (%) | |
| Gastric | 29 (80.6) |
| Gastric-esophageal junction | 7 (19.4) |
| Histological type | |
| Adenocarcinoma | 35 (97.2) |
| Signet cell carcinoma | 1 (2.8) |
| Lauren’s classification—no. (%) | |
| Intestinal | 17 (47.2) |
| Diffuse | 13 (36.1) |
| Mixed | 5 (13.9) |
| Unknown or unclassifiable | 1 (2.8) |
| Clinical T stage—no. (%) | |
| cT3 | 11 (30.6) |
| cT4a | 25 (69.4) |
| Clinical N stage—no. (%) | |
| cN0 | 2 (5.6) |
| cN1 | 18 (50.0) |
| cN2 | 15 (41.7) |
| cN3 | 1 (2.8) |
| Clinical tumor, node, metastases stage—no. (%) | |
| IIB | 2 (5.6) |
| III | 34 (94.4) |
| PD-L1 status—no. (%) | |
| CPS ≥1 | 21 (58.3) |
| CPS <1 | 11 (30.6) |
| Unknown | 4 (11.1) |
CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death ligand-1.